

CARDIOLOGY GRAND ROUNDS



From Human Cells to Human Organs: Building Solutions to CVD

Doris A. Taylor, PhD, FAHA, FACC, FESC

Texas Heart Institute

Director, Regenerative Medicine Research

Director, Center for Cell & Organ Biotechnology

January 11, 2019, 12:00 p.m.

Denton A. Cooley Auditorium

Room C060

Both stem cell biology and scaffold technology are now established as effective regenerative medicine tools. Biocompatible scaffolds provide solid-organ form, function, vasculature, and biological cues, while the advent of inducible pluripotent stem cell technology now makes it possible to generate personalized cells. The concept of engineering bioartificial hearts for transplant is moving closer to reality.

At the conclusion of this conference, participants should be able to:

- Cite advantages and disadvantages of using inducible pluripotent stem cells to recellularize bioengineered scaffolds.
- Identify the primary scientific hurdles that must be overcome to achieve the promise of building bioartificial hearts for transplant.

Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Texas Heart Institute designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Dr. Taylor receives consulting fees, royalties and stock ownership from Miromatrix Medical, Inc.

The Planning Committee has nothing to disclose.

The THI CME Staff have nothing to disclose.

The Program Reviewers have nothing to disclose.